Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

121. Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies Full Text available with Trip Pro

Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies To systematically identify and validate published colorectal cancer risk prediction models that do not require invasive testing in two large population-based prospective cohorts.Models were identified through an update of a published systematic review and validated in the European (...) Prospective Investigation into Cancer and Nutrition (EPIC) and the UK Biobank. The performance of the models to predict the occurrence of colorectal cancer within 5 or 10 years after study enrolment was assessed by discrimination (C-statistic) and calibration (plots of observed vs predicted probability).The systematic review and its update identified 16 models from 8 publications (8 colorectal, 5 colon and 3 rectal). The number of participants included in each model validation ranged from 41 587 to 396

2018 EvidenceUpdates

122. Colorectal Cancer Screening

35% of polyps 6 to 10 mm and 17% of polyps >11 mm [58]. A retrospective study evaluated the diagnostic yield of DCBE examinations performed for colorectal cancer screening in average-risk individuals >50 years of age [59]. The diagnostic yield was 5.1% for neoplastic lesions =10 mm and 6.2% for advanced neoplastic lesions, regardless of size. These diagnostic yields fall within the lower range of those reported for screening colonoscopy (5.0% to 9.5% for colonic neoplasms =10 mm [60-62] and 4.6 (...) % to 11.7% for advanced colonic neoplasms, regardless of size [60,62,63]). Additional data on the effectiveness of the DCBE for detecting colorectal cancer comes from studies in which the imaging history of patients with colorectal cancer was reviewed. In many of these studies, the risk level of patients undergoing DCBE was not reported. Based on this methodology, the sensitivity of DCBE ranges from 75% to 95% [64-66]. This correlates with a large, population-based study that found the overall rate

2018 American College of Radiology

123. Combination drug development in BRAF mutant colorectal cancer Full Text available with Trip Pro

Combination drug development in BRAF mutant colorectal cancer 29854866 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Combination drug development in BRAF mutant colorectal cancer. 51-53 10.18632/oncoscience.399 Lam Michael M Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University (...) of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF mutant colorectal cancer ERK MEK combinations resistance CONFLICTS OF INTEREST The authors declare

2018 Oncoscience

124. Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer Full Text available with Trip Pro

Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer 29854868 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer. 57-58 10.18632/oncoscience.401 Gao Chenxi C Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hu Jing J Department (...) of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF CRC FAK resistance the Wnt/b-catenin pathway CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 16 2018 04 16 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854868 10.18632/oncoscience.401 401 PMC5978442 Sci Signal. 2012 Jan 10;5(206):ra3 22234612 Proc Natl Acad

2018 Oncoscience

125. The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. Full Text available with Trip Pro

The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. The present study was designed to evaluate safety and efficacy of recombinant human granulocyte colony stimulating factor (G-CSF) injection and whether this regimen could reduce the incidence of adverse events caused by chemotherapy.A total of 100 patients with colon cancer who were treated with chemotherapy in our hospital from January 2011 (...) , the incidence of liver dysfunction in the treatment group was lower than that of the control group, without statistical significance. The incidence of myalgia in the treatment was higher than that of the control group without statistical significance.The present study indicated that G-CSF injection after chemotherapy is safe and effective for preventing adverse events in colon cancer patients with chemotherapy.

2018 Revista da Associacao Medica Brasileira (1992) Controlled trial quality: uncertain

126. Perspectives on the evolving state of the art management of gastrointestinal stromal tumours Full Text available with Trip Pro

Perspectives on the evolving state of the art management of gastrointestinal stromal tumours Gastrointestinal stromal tumours (GISTs) represent a very exciting tumour entity for the medical oncologist. There has been extensive clinical and preclinical research dissecting the natural behaviour, molecular landscape and therapeutic responsiveness of this rare mesenchymal tumour. Various molecular subtypes of GIST have a differing prognostic and predictive relevance in the state of the art (...) management of the disease. Emerging mature clinical trial data gathered over the last one and half decade provided substantial molecular profiling information in understanding the success and eventual failure of treatment. In our review of the most relevant literature we aim to guide the clinician in tailoring neoadjuvant, adjuvant and palliative treatment of GIST alongside the different, now well established molecular subgroups of GISTs.

2018 Translational gastroenterology and hepatology

127. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se Full Text available with Trip Pro

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had

2018 ESMO open Controlled trial quality: uncertain

128. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer Full Text available with Trip Pro

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer The International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part (...) of this project, we report safety data from the Japanese ACHIEVE study (JFMC47-1202-C3).ACHIEVE was an open-label, multicentre trial randomising patients with stage III colon cancer to receive 3 m or 6 m of mFOLFOX6/CAPOX after surgery. Choice of regimen was declared before randomisation by a site investigator.Between August 2012 and June 2014, 1313 patients were enrolled and, of those, 1277 were analysed for the safety analysis, with 635 in arm 6 (mFOLFOX6, n=158; CAPOX, n=477) and 642 in arm 3 (mFOLFOX6, n

2018 ESMO open Controlled trial quality: uncertain

129. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Full Text available with Trip Pro

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. The long-term effects of sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality in women and men are unclear.To determine the effectiveness of flexible sigmoidoscopy screening after 15 years of follow-up in women and men.Randomized controlled trial. (ClinicalTrials.gov: NCT00119912).Oslo and Telemark County, Norway.Adults aged 50 to 64 years (...) in women.Norwegian government and Norwegian Cancer Society.

2018 Annals of Internal Medicine Controlled trial quality: predicted high

130. ColonFlag for identifying people at risk of colorectal cancer

methods for colorectal cancer by automatically testing people using routinely available data. It differs from other software algorithms by using machine learning techniques to improve the accuracy of predictions. Current NHS pathway or current care pathway The NHS bowel cancer screening programme offers a guaiac faecal occult blood test (gFOBT) to people aged between 60 and 74 once every 2 years. In 2015, the UK National Screening Committee recommended that the bowel cancer screening programme switch (...) . The data were taken from the KPNW tumour registry. Intervention and comparator(s) ColonFlag compared with the standard of care. ColonFlag for identifying people at risk of colorectal cancer (MIB142) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 13Key outcomes AUC=0.80±0.01. OR=34.7 (95% CI 28.9 to 40.4) for a specificity of 99%. ColonFlag was found to be more accurate at detecting right-sided CRCs than left

2018 National Institute for Health and Clinical Excellence - Advice

131. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Full Text available with Trip Pro

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Volume 154, Issue 3, Pages 736–745.e14 Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations x Denis Hadjiliadis Affiliations Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania Correspondence Reprint (...) Institute of Oncology, Milan, Italy 5 , x Albert B. Lowenfels Affiliations New York Medical College, Valhalla, New York 6 on behalf of the x Cystic Fibrosis Colorectal Cancer Screening Task Force x Amy Leigh Braid x Amy Leigh Braid , x Joanne Cullina x Joanne Cullina , x Anne Daggett x Anne Daggett , x Aliza Fink x Aliza Fink , x Andrea Gini x Andrea Gini , x Denis Hadjiliadis x Denis Hadjiliadis , x Paul F. Harron x Paul F. Harron , x Sarah Hempstead x Sarah Hempstead , x Alexander Khoruts x Alexander

2018 Cystic Fibrosis Foundation

132. Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery Full Text available with Trip Pro

Computed Tomography Colonography vs Colonoscopy for Colorectal Cancer Surveillance After Surgery Recommendations for surveillance after curative surgery for colorectal cancer (CRC) include a 1-year post-resection abdominal-pelvic computed tomography (CT) scan and optical colonoscopy (OC). CT colonography (CTC), when used in CRC screening, effectively identifies colorectal polyps ≥10 mm and cancers. We performed a prospective study to determine whether CTC, concurrent with CT, could substitute (...) for OC in CRC surveillance.Our study enrolled 231 patients with resected stage 0-III CRC, identified at 5 tertiary care academic centers. Approximately 1 year after surgery, participants underwent outpatient CTC plus CT, followed by same-day OC. CTC results were revealed after endoscopic visualization of sequential colonic segments, which were re-examined for discordant findings. The primary outcome was performance of CTC in the detection of colorectal adenomas and cancers using endoscopy

2018 EvidenceUpdates

133. Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer Full Text available with Trip Pro

Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer Previous studies reported that black vs white disparities in survival among elderly patients with colorectal cancer (CRC) were because of differences in tumor characteristics (tumor stage, grade, nodal status, and comorbidity) rather than differences in treatment. We sought to determine the contribution of differences in insurance, comorbidities, tumor characteristics, and treatment receipt (...) to disparities in black vs white patients with CRC 18-64 years old.We used data from the National Cancer Database, a hospital-based cancer registry database sponsored by the American College of Surgeons and the American Cancer Society, on non-Hispanic black (black) and non-Hispanic white (white) patients, 18-64 years old, diagnosed from 2004 through 2012 with single or first primary invasive stage I-IV CRC. Each black patient was matched, based on demographic, insurance, comorbidity, tumor, and treatment

2018 EvidenceUpdates

134. New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer (Abstract)

New-Onset Cardiovascular Morbidity in Older Adults With Stage I to III Colorectal Cancer Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I (...) to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408). Results Median age at diagnosis of colorectal cancer was 78 years (range, 66 years to 106 years), and median follow-up was 8 years since diagnosis. The 10-year cumulative incidence of new-onset CVD and CHF were 57.4% and 54.5% compared with 22% and 18% for control, respectively ( P < .001

2018 EvidenceUpdates

135. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) Full Text available with Trip Pro

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab (...) maintenance and with no treatment (observation) during CFI subsequent to induction chemotherapy with 12 cycles of fluorouracil, leucovorin, and irinotecan plus bevacizumab. After disease progression, the induction regimen was repeated for eight cycles, followed by a new CFI. Results From March 2010 to July 2013, 491 patients were randomly assigned. Disease progression or death occurred during induction chemotherapy in 85 patients (17%); 261 patients (53%) had at least one reinduction, 107 (22%) had two

2018 EvidenceUpdates

136. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. Full Text available with Trip Pro

of therapy was noninferior to 6 months, with a 3-year rate of disease-free survival of 83.1% and 83.3%, respectively (hazard ratio, 1.01; 95% CI, 0.90 to 1.12). Among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; P=0.01 for superiority).Among patients with stage III colon cancer receiving (...) Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted

2018 NEJM

137. Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors Full Text available with Trip Pro

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors This study was conducted to assess the adverse reactions caused by multi-target tyrosine kinase inhibitor treatment of gastrointestinal tumors.We carried out a retrospective study of drug-related adverse reactions in 115 patients who were treated with sorafenib, sunitinib, and imatinib for primary hepatocellular carcinoma or gastrointestinal stromal tumors from October 2003 to March 2012 at the Peking (...) University International Hospital.The total incidence of adverse reactions of sorafenib, sunitinib, and imatinib in patients with hepatocellular carcinoma and gastrointestinal stromal tumors was > 80%. The main adverse reactions of sorafenib were hypertension in 38 patients (33.3%) and diarrhea in 28 patients (24.4%). Sunitinib was associated with higher incidence and greater grade 3-4 toxicity. The common toxicities were skin color changes in 105 patients (90.9%), hand-foot skin reactions in 65 patients

2018 Thoracic cancer

138. Impact of GI Tumor Board on Patient Management and Adherence to Guidelines Full Text available with Trip Pro

Impact of GI Tumor Board on Patient Management and Adherence to Guidelines As the burden of cancer on the population and the health care system continues to increase with more complicated treatment options, the need for multidisciplinary teams to be as efficient as possible becomes more vital. Our study aimed to evaluate the consistency of GI Tumor Board (GI TB) recommendations with international guidelines, the adherence of physicians involved in patient care to TB recommendations (...) , and the impact on the management of patients.A prospective cohort study was conducted from January to June 2016 at our institution, which is a major tertiary hospital that provides comprehensive cancer care. All cases presented at the GI TB during this period were included. Data regarding adherence to National Comprehensive Cancer Network guidelines, adherence to TB recommendations, and changes made to the management of patients were collected weekly from the GI TB in a data collection form.Of the 104

2018 Journal of global oncology

139. Non-exposed endoscopic wall-inversion surgery for gastrointestinal stromal tumor Full Text available with Trip Pro

Non-exposed endoscopic wall-inversion surgery for gastrointestinal stromal tumor Laparoscopic and endoscopic cooperative surgery (LECS) is an accepted method of laparoscopic wedge resection, which is minimally invasive, for gastrointestinal stromal tumors (GISTs). We established a type of LECS achieving a full-thickness resection, non-exposed endoscopic wall-inversion surgery (NEWS), in an effort to prevent exposure of the peritoneal cavity to gastric intraluminal contents. We employed (...) this surgical technique in 28 gastric GIST patients. We failed to complete NEWS in the initial two patients and in one patient with a large tumor (40 mm × 35 mm), but otherwise carried out the procedure successfully. Although a learning effect is speculated to occur, based on a decreasing trend in the operation time, the median operation time was 184 minutes showing that NEWS is still a time-consuming method. No significant differences were recognized in tumor size or location, except near

2018 Translational gastroenterology and hepatology

140. Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 Full Text available with Trip Pro

Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016 Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. In Latin America and the Caribbean, it has a mortality of 56%. The median overall survival for patients with metastatic colorectal cancer (mCRC) is currently estimated as ~30 months, which has substantially improved through strategic changes in treatment (...) and in the management of patients. As opposed to other metastatic cancers where first-line regimens are often determined, mCRC requires special attention because there is controversy in the possible combinations of the available drugs and the different periods of duration for each patient. Each combination must seek to be effective and to generate the minimum adverse effects as possible. Instead of giving the first-line regimen until the tumour progresses, treatment is often individualised. Furthermore, up to 60

2018 ESMO open